# 14.2 TRIGLYCERIDES LONG CHAIN with GLUCOSE POLYMER, triglycerides long chain with glucose polymer oral liquid, 27 x 200 mL cartons, Sno-Pro®, Nutricia Australia Pty Ltd

1. **Purpose of application**
	1. To request a Restricted benefit listing for patients with proven inborn errors of protein metabolism (IEM) who are unable to meet their energy requirements with permitted food and formulae.
2. **Requested Listing**
	1. *(The requested listing has been reformatted by the Secretariat for compatibility with PharmCIS).*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name, Restriction,Manner of administration and form |  Max. Qty | №.ofRpts | Dispensed Price for Max. Qty | Proprietary Name and Manufacturer |
| TRIGLYCERIDES LONG CHAIN WITH GLUCOSE POLYMERtriglycerides long chain with glucose polymer oral liquid, 27x 200 mL cartons |   4  | 5 | $361.64 | Sno-Pro® | SB |
| **Condition/Indication:** | Inborn errors of protein metabolism |
| **Restriction:** | Restricted benefit |
| **Clinical criteria:** | Patient must be unable to meet energy requirements with permitted food and formulae |

* 1. The submission requested listing at the same price per kJ of energy as the comparator ProZero. The submission claimed there will be no additional cost to the PBS to list SnoPro®. SnoPro® is not expected to grow the market as the expectation is that patients will switch from the existing product and comparator ProZero.
	2. The Nutritional Products Working Party (NPWP) advised that the current maximum quantity for ProZero is too high. It was reported that wastage is an issue with the current PBS availability of ProZero, with product going out of date prior to it being used. It was noted that ProZero does not appear to be being given to achieve 30% of dietary energy requirements, and that smaller amounts are being used. Given this, the NPWP considered that a lesser maximum quantity of 2 boxes (x 27 x 200 mL cartons) for Sno-Pro would be more appropriate.
1. **PBAC Outcome**
	1. The PBAC noted that the NPWP supported the listing of SnoPro with a maximum quantity of 2 boxes of 27 x 200 mL cartons. As advised by the NPWP, the PBAC recommended listing with the same restriction wording as currently applies to the comparator ProZero.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Name, Restriction,Manner of administration and form |  Max. Qty | №.ofRpts | Dispensed Price for Max. Qty | Proprietary Name and Manufacturer |
| TRIGLYCERIDES LONG CHAIN WITH GLUCOSE POLYMERtriglycerides long chain with glucose polymer oral liquid, 27x 200 mL cartons |   2  | 5 | $TBC based on current price per kJ as ProZero | Sno-Pro® | SB |
| **Condition/Indication:** | Inborn errors of protein metabolism |
| **Restriction:** | Restricted benefit |
| **Clinical criteria:** | Patient must be unable to meet energy requirements with permitted food and formulae |

1. **Context for Decision**

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

1. **Sponsor’s Comment**

The sponsor had no comment.